Cohance Lifesciences invests in ADC firms
Analysis based on 7 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026
The investment signals Cohance's strategic expansion into the ADC market, potentially enhancing its growth prospects and attracting investor interest. The transactions are expected to strengthen Cohance's integrated CRDMO capabilities and control over Aruka's proprietary ADC platform, which may positively impact its valuation and market position.
Eris Lifesciences, formerly Suven Pharmaceuticals, announced an $18 million investment to strengthen its antibody-drug conjugate (ADC) strategy. The company will invest $13 million in NJ Bio, increasing its ownership from 56% to 67.3%, and $5 million in Aruka Bio, acquiring a 65% controlling stake. The transactions, funded through internal accruals, aim to integrate NJ Bio's customer-facing contract research and manufacturing services with Cohance's manufacturing capabilities, while Aruka Bio will focus on developing next-generation ADCs. The restructuring follows a review of NJ Bio's performance since December 2024. Completion is expected by the end of September 2026, subject to definitive agreements and customary conditions. Dr. Naresh Pal will continue to lead NJ Bio and eventually move full-time to Aruka as CEO.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard